Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 PK comparability of TAK-881 vs HYQVIA in CIDP
jRCT2041250014Phase 3Recruiting
- Sponsor
- Takeda
- Start
- May 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 3, open-label, single-arm trial of TAK-881 in chronic inflammatory demyelinating polyneuropathy (CIDP), sponsored by Takeda. Primary endpoint: Baseline-uncorrected AUC0-tau,ss based on total IgG levels. Started May 2025; status: recruiting.
02
Drugs
TAK-881
03
Conditions
chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on jRCT2041250014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041250014.